Sanofi-Aventis said on April 3rd it still has high hopes for diet drug rimonabant (Acomplia / Zimulti), even though it was rejected by a U.S. FDA advisory panel last year and recent clinical trial news has been less than wildly encouraging.

Marc Cluzel, Sanofi’s head of research, said in a round of interviews in London that he continues to believe Acomplia can be a winner.

Acomplia, which was to have been marketed in the United States as Zimulti, was withdrawn from FDA consideration last June after an expert panel unanimously recommended against approval out of concern over depressive and suicidal side-effects.

Data from a new clinical trial of possible use of Acomplia in slowing progression of coronary artery disease was reported this week along with news that 43.4 percent of patients who got rimonabant in this trial suffered psychiatric side effects such as anxiety and depression.

While the results of the heart trial were ambiguous at best, Cluzel put a positive face on it — and reiterated that Sanofi intends to resubmit rimonabant to the FDA and regulators worldwide in 2009 for approval as a treatment for type 2 diabetes.

Acomplia diet pill is finally approved for sale in the UK. Developed by Sanofi, diet pill Acomplia (rimonabant) was highly anticipated pill for weight loss which was formally launched on June 28th in Britain. Now the diet drug can be purchased by patients who obtain a prescription from a general practitioner.

Rimonabant is not only beneficial for obese people but it is also prescribed to those who wish to quit smoking. Although primarily it is for obese people, still it’s usefulness for the smoking cessation also.

Although acomplia benefits more of the obese people, still it’s usefulness for the community of smokers cannot be left unnoticed. Its trial has confirmed that it is an effective way to relinquish smoking. Though acomplia is one of the most promising weight loss drugs, it should still not be taken without the consultation of a doctor. No one can better advise you on the drug than your physician. He may not allow you to take acomplia if you have had some serious health problems in the past.

What were the results of Acomplia Clinical trial studies?

• In clinical studies, Acomplia has been shown to improve a wide array of cardiometabolic risk factors as well as promoting sustained weight loss4,5.
• Approximately half of the observed improvement in HDL-cholesterol, triglycerides and HbA1C (an indicator of blood sugar control) in patients who received Acomplia 20mg was beyond that expected from weight loss alone.

 Acomplia online

Sanofi-Aventis  said on Tuesday the European Commission had endorsed the positive opinion of the European Medicines Evaluation Agency (EMEA) for its anti-obesity drug Acomplia (rimonabant) to include type 2 diabetes trial results into the European label (section 5.1). The update is based on the results of the SERENADE study, which showed rimonabant 20 mg significantly improved glycemic control in newly diagnosed naive type 2 diabetic patients, the statement said.

The study also demonstrated that rimonabant 20mg had additional benefits on cardio-metabolic risk factors beyond diabetes.

Rimonabant Acomplia online works by blocking receptors of a substance called cannabinoid 1, which stimulates hunger and other cravings in the brain and is also present in fat tissue. This receptor is also present in the fat tissue and controls the hunger in the brain. So when you take this rimonabant drug, you will automatically eat less because you do not feel hunger. As a result you will take less food which helps you to reduce your cholesterol levels. When you start losing weight, the first place you will lose body fat is your mid-section. And your cholesterol will go down and your blood pressure will return to healthy levels.

Tipped as a future multibillion-dollar-a-year seller, Acomplia is all set to surprise the weight loss drug market. Acomplia has dual advantage attached to it property since it can help people both lose weight and quit smoking. That is really lot more than you can ever expect from even a miracle pill.

Acomplia pills are the newest entrant in the UK pharmaceutical market making waves for its dual nature of weight loss and smoking cessation property. As the wonder drug Accomplia online is finally approved for sale through prescription, we have got numerous queries on the online buying options related to this drug.

The drug, rimonabant, which the French company Sanofi-Aventis hopes to sell under the brand name Acomplia, trimmed nearly 16 pounds on average from people taking the optimal dose for two years, compared with 5.5 pounds for those who took dummy pills, doctors reported Tuesday at a cardiology conference.

Acomplia works in an entirely different way, by blocking a “pleasure center” in the brain, leading people to eat less and acting directly on fat cells to prevent weight gain. Company studies suggest it also might help people quit smoking.

‘Miracle’ Weight Loss Pill (Acomplia)-May Offer Obesity Cure

More and more studies show that this medication helps patients loose weight when compared to a placebo. Most of the weight reduction results from patients limiting the number of calories they consume on a daily basis. Acompliaworks different it helps to control appetite.This is something that for many patients involved in weight reduction programs is a major obstacle to achieve.

Even though the safety of the Acomplia is being monitored very careful , no major problems have been reported. But there are some mild side effects that people should be aware of, including nausea, dizziness or depression.

The Zimulti Acomplia Report

Now that a promising new prescription weight loss drug, rimonabant, it is today available in the U.K., Germany and 44 other countries, the launch of the most anticipated weight-loss Drug since Fen-phen is generating a great deal of excitement among millions of obese people  and seriously overweight Americans and Europeans.
The medication, sold in Europe as Acomplia, may ultimately be sold in the United States as Zimulti — but that day seems to be  several years off after an FDA advisory panel voted against sale of rimonabant in summer 2007 out of concern over its depressive side effects.
The Rimonabant Zimulti Acomplia Report, updated every day, will track the continuing efforts of Sanofi Avensis to get Rimonabant approved for sale on the U.S. market The Zimulti Acomplia Report also will provide news,informations and reviews about  rimonabant so those eager to try this new anti-obesity drug will have the latest information on availability, weight-loss results and side-effects.
Side effects of Acomplia Rimonabant were described as minor and temporary, the most frequent    being diarrhea, nausea, vomiting and dizziness. More severe anticipated side effects, especially    depression, did not materialize. it caused  nausea in 13% of patients, vs. in 4% of those who got    placebo.

The year-long Rimonabant in Obesity-Diabetes study, a multi-center trial which enrolled 1,000 obese patients with type 2 diabetes, will be the last of the four major Acomplia studies to report trial results before U.S. and European regulators are expected to act on Sanofi-Aventis’ application to bring the drug to market.

In this trial, researchers compared weight-loss, improvements in metabolic variables, and reduction in cardiovascular risk factors for obese diabetics who took Acomplia compared to those on a placebo.

RIO-Diabetes, the multicenter, randomized, double-blind, placebo-controlled trial

of rimonabant in overweight/obese type 2 patients, evaluated weight loss, metabolic

variables and cardiovascular risk reduction; and findings from the Diabetes Prevention

Program follow-up studies indicate that complications can occur even earlier than we

previously thought – well before the actual cut-point for diagnosing type 2 diabetes

RIO-Diabetes, the multicenter, randomized, double-blind, placebo-controlled trial

of rimonabant in overweight/obese type 2 patients, evaluated weight loss, metabolic

variables and cardiovascular risk reduction; and findings from the Diabetes Prevention

Program follow-up studies indicate that complications can occur even earlier than we

previously thought – well before the actual cut-point for diagnosing type 2 diabetes

RIO-Diabetes, the multicenter, randomized, double-blind, placebo-controlled trial

of rimonabant in overweight/obese type 2 patients, evaluated weight loss, metabolic

variables and cardiovascular risk reduction; and findings from the Diabetes Prevention

Program follow-up studies indicate that complications can occur even earlier than we

previously thought – well before the actual cut-point for diagnosing type 2 diabetes

Announcement of the results of the RIO-Diabetes trial is slated for a symposium on “Late-Breaking Clinical Trials” scheduled to be held at 2 pm PDT June 12th.

Researchers have hinted privately to reporters that the results are consistent with the highly encouraging results from their three studies reported earlier — RIO-North America, RIO-Europe and RIO-Lipids.

The fact that the results are going to be presented at the highest-profile symposium at the American Diabetes Association meeting — only weeks after Sanofi filed for approval of the drug with the U.S. Food and Drug Administration and European regulators — also strongly suggests more positive news is forthcoming.

More related articles: Acomplia news report

                                     Rimonabant acomplia competitor

An announcement was made about Sanofi-Aventis.This refears to  the launch of Acomplia (rimonabant), a  new  medication that treats  abdominally obese persons which presents cardio metabolic risk cluster.

This medication was approved from the European Medicines Evaluation Agency (EMEA) in order  to be used,but combined  with diet and sport and it’s ment to the treat  obesity with cardio metabolic risk cluster.People can buy Acomplia  already in more that 15 European states, including very important states like Germany and the UK.

This  new obesity drug can reduce very much the  blood sugar levels in persons which have type 2 diabetes and in the same time it helps  this persons to reduce their body weight. Acomplia way of working is  by select and block the  receptors that are located in the brain and in peripheral organs important in glucose and lipid metabolism,and that  includes the liver, gastrointestinal tract, adipose tissue, and muscle. The medication is decreasing the over activity of the endocannabinoid system (EC system). The EC system was a short time ago characterized as a physiological system that includes receptors such as the CB¹ receptor, and scienties think that in order  to play an very important role in controlling energy balance ,in regulating body weight and glucose and lipid metabolism.So it’s ok for people to use and buy acomplia.

Buy Acomplia a really good Diet Pill

Acomplia is a new medication which helps people to lose weight, rimonabant (also named Acomplia), and it is helping also patiens with diabetes type 2. It helps people lose pounds and meanwhile it  makes patiens have a much better blood sugar levels,so  science people say. The buy of acomplia is being approved and tested in Europe. Despite that fact, Acomplia hasn’t been approved for use in the United States,at least for now. This discovering tell us that acomplia can be used as a new alternative in treating diabetes,despite that other drugs have failed and couldn’t improve people health. In one study, Andre Thomson, and another scientice people had a look on the  effects of acomplia in more that 1,000 persons with a very hard to controll type 2 diabetes.

All the people that participated had obesity or overweight and other treatment with other drugs failed. Those people were given a low-calorie diet plan and werw advised to be more physically active. They also toke  acomplia at a dose of either 5 milligrams or 20 milligrams per day, or a placebo.Results were amaizing.So ,you can buy acomplia and use it and not worry about the result,becouse they will surprise you.

Acomplia(Rimonabant) is a medication that treats very well obesity by making people to eat less has been launched in the UK.

Acomplia(Rimonabant) is the first drug that can reduce  the body’s appetite, metabolism and energy that we can use. Trials have proved that it can reduce weight by a tenth.

UK Experts think that acomplia(rimonabant) does  not  have the property to replace healthy food and sport exercise.

In this country , statistics showed that one in five men and a quarter of women are obese.

Price

The cost of acomplia(rimonabant) in very big,about over £55 for a month’s treatment and this it may go to a  cost of billions of pounds of money for the NHS.

The drug is going to be assessed by NHS advisers the National Institute for Health and Clinical Excellence.

The review is going to be given sometime in the next two years and NHS bosses warned the public that is not good to expect its widespread use right away.

The chief executive of the NHS Confederation,Gill Morgan, said primary care trusts may be reluctant to prescribe the medication despite of NICE guidance.

“PCTs receive a fixed sum of money to put to the diposition of their local community all the services and have to asume very hard decisions on competing priorities.”

Also she said that weight loss was “predominantly about diet and sport exercise”.

The producer of acomplia(rimonabant), Sanofi Aventis, has said that the drug represents the best value for money when set against the £7bn per year cost of living behind obesity.

In a lot of trials that were involving more than 6,000 patients in the US and Europe, a quarter lost more than 10% of their initial body weight only in a year. About half lost more than 5% in the same period.

Some other anti-obesity drugs are available at this moment, but acomplia (rimonabant) is the only one to target the endocannabinoid system, whichis responsible with the body’s appetite.

Side effects of acomplia(rimonabant) in some patients are some like nausea, dizziness and anxiety.

The reckoning day  for 2007 has now come and and also past for the FDA to review the rimonabant medication. Rimonabant is a medication known as well as Acomplia specialy in Europe,but also in other  states and Zimulti is the name that rimonabant has  in the United States. June 13th, the FDA vote was negative regarding the recommendasion of this rimonabant to hit the  pharmacies all over USA. What is  the meaning of this negative answer  for Sanofi-Aventis and what is going to happen with this medication in the future regarding the space of  the United States?
Rimonabant has been used in the past in many European states for  treating obesity. It works really different than much more other diet medications and it also  has some other benefits. Some of the possible benefits of this medication is that it  is increasing the “good” cholesterol,and in the same time is reducing “bad” cholesterol and it is possible in the future to  help smokers quit smoking . Basically speaking, Rimonabant is blocking receptors who are located in the brain and are responsible for food eagerness. When you’re eating less, it means,generally speaking that you are consuming less calories and that the conclusion is that you lose weight..

   Despite the fact that we don’t know all that happend on in the FDA meeting, we do know what were the discussions  that some that where brought up about this drug. One of the most important obstacles they had handlle it with  it’s the possible psychiatric side effects ,specially suicidal influences. The FDA panel was not satisfied with the amount off sideeffect and opinons they had regarding rimonabanr. Probably they will supervise it and that includes watching the feedback responses coming in from other doctors from all over the globe. It seems likely that a 50 month trail will then determine if this medication is going to be  accepted into the USA market, but this trail would not be complete until 2010. The FDA had been against for allowing drugs to hit the USA pharmacies also in the past, because they considered a too short of a study period. It seems that with such a possible popular medication such as acomplia or rimonant, that the FDA did not want to not know all aspects of this medication before they will accepted it in the USA.